Immunoregulatory molecule expression on extracellular microvesicles in people living with HIV.

chronic immune activation extracellular vesicle (EV) immune activation (IA) immunoregulatory molecules microparticles (MPs) people living with HIV (PLWH)

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2024
Historique:
received: 11 12 2023
accepted: 20 02 2024
medline: 19 3 2024
pubmed: 19 3 2024
entrez: 19 3 2024
Statut: epublish

Résumé

People living with HIV (PLWH) now benefit from combined antiviral treatments that durably control viral replication. These antiretroviral treatments decrease mortality and improve quality of life in PLWH, but do not completely control the excessive non-specific activation of the immune system in PLWH. This chronic immune activation is a key element of HIV immunopathology that contributes to the pathophysiology of inflammatory comorbid conditions, such as cardiovascular disorders, cancer and autoimmune diseases. Circulating non-exosomal extracellular vesicles, also known as microparticles (MPs) are detected in these diseases and have been linked to immune activation. The objective of this study was to characterize the MPs present in PLWH and to assess their association with chronic immune activation. We performed flow cytometry for the complete phenotypic characterization of MPs from fresh plasma from PLWH and from people without HIV as the control group. The absolute number, size and cellular origin of MPs were evaluated. The immunoregulatory profile was determined by cell origin, for MPs derived from platelets (PMPs), monocytes (MMPs) and T lymphocytes (LMPs). PLWH had significantly more circulating MPs than controls, for MPs of all sizes originating from T lymphocytes, red blood cells, neutrophils, dendritic cells, B lymphocytes and endothelial cells. PMPs and MMPs were not more numerous in PLWH, but the immunoregulatory phenotypes of these MPs differed between PLWH and controls. These differences in immunoregulatory molecule expression profile were also observed for LMPs. PDL1, ICOSL, CCR5, TGFβ1, MHC classes I and II, TRAIL, CXCR4, OX40, DC-SIGN, CTLA4 and PDL2 were more strongly expressed on the surface of MPs from PLWH than on those from controls. MPs are an important element in intercellular communication, making it possible to transfer phenotypes and functions to immune cells. The significantly higher numbers of MPs expressing diverse immunomodulatory molecules in PLWH may make a major contribution to the maintenance and/or the development of immune-cell activation in these individuals.

Identifiants

pubmed: 38500878
doi: 10.3389/fimmu.2024.1354065
pmc: PMC10944887
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1354065

Informations de copyright

Copyright © 2024 Neyrinck-Leglantier, Tamagne, Ben Rayana, Many, Vingert, LeGagneux, Delorme, Andrieu, Boilard, Cognasse, Hamzeh-Cognasse, Perez-Patrigeon, Lelievre, Pirenne, Gallien and Vingert.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Deborah Neyrinck-Leglantier (D)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Marie Tamagne (M)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Raida Ben Rayana (R)

Service de Maladies Infectieuses et Immunologie Clinique, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Souganya Many (S)

Institut Cochin, Inserm U1016, Centre National de la Recherche Scientifique (CNRS) UMR8104, Université Paris-Cité, Paris, France.

Paul Vingert (P)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Julie LeGagneux (J)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Adèle Silane Delorme (AS)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Muriel Andrieu (M)

Institut Cochin, Inserm U1016, Centre National de la Recherche Scientifique (CNRS) UMR8104, Université Paris-Cité, Paris, France.

Eric Boilard (E)

Faculté de Médecine and Centre de Recherche ARThrite, Université Laval, Québec, QC, Canada.
Centre de Recherche du Centre Hospitalier Universitaire de Québec, Université Laval, Québec, QC, Canada.

Fabrice Cognasse (F)

Etablissement Français du Sang Auvergne-Rhône-Alpes, Saint-Etienne, France.
SAINBIOSE, INSERM, U1059, University of Lyon, Saint-Etienne, France.

Hind Hamzeh-Cognasse (H)

SAINBIOSE, INSERM, U1059, University of Lyon, Saint-Etienne, France.

Santiago Perez-Patrigeon (S)

Division of Infectious Diseases, Queen's University, Kingston, ON, Canada.

Jean-Daniel Lelievre (JD)

Service de Maladies Infectieuses et Immunologie Clinique, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

France Pirenne (F)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Sébastien Gallien (S)

Service de Maladies Infectieuses et Immunologie Clinique, Centre Hospitalier Universitaire Henri-Mondor, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Est Créteil (UPEC), Créteil, France.

Benoît Vingert (B)

Univ Paris Est-Creteil (UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Mondor de la Recherche Biomédicale (IMRB), Creteil, France.
Etablissement Français du Sang (EFS), Ivry-sur-Seine, France.
Laboratory of Excellence, Biogénèse et Pathologies du Globule Rouge (GR-Ex), Paris, France.

Classifications MeSH